Literature DB >> 18037926

Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission.

R Exley1, S J Cragg.   

Abstract

The effects of nicotine on dopamine transmission from mesostriatal dopamine neurons are central to its reinforcing properties. Only recently however, has the influence of presynaptic nicotinic receptors (nAChRs) on dopaminergic axon terminals within striatum begun to be understood. Here, rather than simply enhancing (or inhibiting) dopamine release, nAChRs perform the role of a presynaptic filter, whose influence on dopamine release probability depends on presynaptic activity in dopaminergic as well as cholinergic neurons. Both mesostriatal dopaminergic neurons and striatal cholinergic interneurons play key roles in motivational and sensorimotor processing by the basal ganglia. Moreover, it appears that the striatal influence of dopamine and ACh cannot be fully appreciated without an understanding of their reciprocal interactions. We will review the powerful filtering by nAChRs of striatal dopamine release and discuss its dependence on activity in dopaminergic and cholinergic neurons. We will also review how nicotine, acting via nAChR desensitization, promotes the sensitivity of dopamine synapses to activity. This filtering action might provide a mechanism through which nicotine promotes how burst activity in dopamine neurons facilitates goal-directed behaviour and reinforcement processing. More generally, it indicates that we should not restrict our view of presynaptic nAChRs to simply enhancing neurotransmitter release. We will also summarize current understanding of the forms and functions of the diverse nAChRs purported to exist on dopaminergic axons. A greater understanding of nAChR form and function is imperative to guide the design of ligands with subtype-selective efficacy for improved therapeutic interventions in nicotine addiction as well as Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037926      PMCID: PMC2268048          DOI: 10.1038/sj.bjp.0707510

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  193 in total

1.  Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum.

Authors:  S N Haber; J L Fudge; N R McFarland
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

2.  Presynaptic nicotinic receptors modulating dopamine release in the rat striatum.

Authors:  S Wonnacott; S Kaiser; A Mogg; L Soliakov; I W Jones
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

3.  Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo.

Authors:  F Gonon
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

4.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

5.  Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.

Authors:  M R Picciotto; M Zoli; R Rimondini; C Léna; L M Marubio; E M Pich; K Fuxe; J P Changeux
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

6.  Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine.

Authors:  C P Fenster; M F Rains; B Noerager; M W Quick; R A Lester
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

7.  Nicotinic receptors and Parkinson's disease.

Authors:  M Quik; G Jeyarasasingam
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

8.  Nicotine activates and desensitizes midbrain dopamine neurons.

Authors:  V I Pidoplichko; M DeBiasi; J T Williams; J A Dani
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

Review 9.  Diffuse transmission by acetylcholine in the CNS.

Authors:  L Descarries; V Gisiger; M Steriade
Journal:  Prog Neurobiol       Date:  1997-12       Impact factor: 11.685

10.  Up-regulation of brain nicotinic acetylcholine receptors in the rat during long-term self-administration of nicotine: disproportionate increase of the alpha6 subunit.

Authors:  Steven L Parker; Yitong Fu; Kathleen McAllen; Jianhong Luo; J Michael McIntosh; Jon M Lindstrom; Burt M Sharp
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

View more
  115 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2010-08-23       Impact factor: 4.436

Review 3.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

4.  Effects of dopamine D1-like and D2-like antagonists on cocaine discrimination in muscarinic receptor knockout mice.

Authors:  Morgane Thomsen; Simon Barak Caine
Journal:  Eur J Pharmacol       Date:  2016-02-11       Impact factor: 4.432

5.  Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Authors:  Xiomara A Perez; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-10-13       Impact factor: 5.372

6.  Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

Authors:  Xiomara A Pérez; Maryka Quik
Journal:  Mol Cell Pharmacol       Date:  2011

7.  Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment.

Authors:  Xiomara A Perez; Kathryn T O'Leary; Neeraja Parameswaran; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2009-01-14       Impact factor: 4.436

Review 8.  PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.

Authors:  Robert W Gould; Angela N Duke; Michael A Nader
Journal:  Neuropharmacology       Date:  2013-02-28       Impact factor: 5.250

9.  Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.

Authors:  Stefano Pallanti; Silvia Bernardi; Sarah Antonini; Nikhilesh Singh; Eric Hollander
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

10.  Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia.

Authors:  Anthony M Downs; Xueliang Fan; Christine Donsante; H A Jinnah; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2019-01-30       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.